Gaps in Diagnostic and Therapeutic Options for Clostridioides difficile in Immunocompromised Children in Latin America: A PRINCIPAL network perspective

Clicks: 11
ID: 327369
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #139 of 147 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 147 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Clostridioides difficile infection (CDI) is a major cause of healthcare-associated diarrhea, particularly in immunocompromised children. Advances such as multi-step diagnostic algorithms, the introduction of fidaxomicin, and the use of fecal microbiota transplantation for recurrent episodes have improved outcomes in these patients. However, access to these diagnostic and therapeutic tools remains limited across Latin America. We aimed to assess CDI-related resources and practices across Latin America tertiary hospitals that care for children with cancer and other immunosuppressive conditions and identify existing gaps in diagnosis and management. Methods We conducted a survey among members of the Pediatric Cancer Infection Preventionists and Infectious Diseases Specialists Network in Latin America (PRINCIPAL). The survey assessed the availability of diagnostic tools (including enzyme immunoassays and nucleic acid amplification tests) and therapeutic options (metronidazole, vancomycin, fidaxomicin, fecal microbiota transplantation. We then compared current international recommendations for CDI diagnosis and treatment with their reported availability in tertiary hospitals in Latin America that treat children with cancer and other immunosuppressive conditions. Results Thirty-six members of the PRINCIPAL Network from 30 tertiary institutions completed the survey. Diagnostic techniques available included glutamate dehydrogenase (GDH) antigen testing in 47.2% of centers, A/B toxin immunoassays in 69.4%, and nucleic acid amplification tests (NAAT) in 91.7%. Therapeutically, metronidazole and vancomycin were available in 97.2% and 91.7% of hospitals, respectively. No institution reported access to fidaxomicin, and fecal microbiota transplantation for recurrent CDI had not been performed in any center. Conclusion Significant gaps exist in both diagnostic and therapeutic possibilities for CDI in Latin America for immunocompromised children. Despite international advances in diagnostics and treatment, implementation of these innovations remains limited across Latin American centers. Closing these gaps will require strengthening laboratory capacity, improving access to advanced diagnostics, and expanding therapeutic options.
Reference Key
openalex_W7204663594 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Francisco Alcalde, Valentina Gutiérrez
Are you one of these authors? Claim your profile
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag070/piag070.067
URL
https://academic.oup.com/jpids/article-pdf/15/Supplement_2/S29/70833206/piag070.067.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.